This study is a single centre feasibility trial. The trial will recruit men with intermediate risk localised prostate cancer who will all receive targeted dose (escalated/de-escalated dose directed by MRI) 5 fraction SBRT to the prostate.
Trial Objectives are:
1. Primary To develop a 5 fraction de-escalated dose SBRT protocol capable of reducing side effects 2. Secondary
* To assess levels of acute GU and GI toxicity (CTCAE) * To assess levels of late GU and GI toxicity (CTCAE) * To assess late sexual quality of life (expanded EPIC, IIEF-5) * To assess biochemical relapse-free survival at 2
Men aged ≥18 years
Histological confirmation of prostate adenocarcinoma requiring radical radiotherapy
Gleason score 3+3, 3+4 or 4+3 (Grade groups 1, 2 or 3)
MRI stage T2 or less (as staged by AJCC TNM 2018)
Contraindications to MRI (e.g. pacemaker, potentially mobile metal implant, claustrophobia)
IPSS 19 or higher
High grade disease (GG3) occult to MRI-defined lesion
Post-void residual >100 mls, where known